DIVISLAB2018-07-012018-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member DIVISLAB2018-07-012018-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2018-04-01 2019-03-31 2018-10-19 INR Lakhs Half yearly Single segment Pharmaceuticals 2018-07-01 2018-09-30 Unaudited Standalone 12850000000.00 800500000.00 13650500000.00 5556300000.00 0.00 -823900000.00 1346600000.00 2400000.00 423900000.00 1629700000.00 8135000000.00 5515500000.00 0.00 5515500000.00 1476100000.00 62900000.00 1539000000.00 0.00 3976500000.00 0.00 0.00 0.00 3976500000.00 1700000.00 3978200000.00 0.00 0.00 0.00 0.00 530900000.00 2 14.98 14.98 0.00 0.00 14.98 14.98 (1)The above results, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 27th October, 2018.(2)Results for the quarter and period ended 30th September 2018 were subjected to �limited review� by the Auditors and their report contains no qualification.(3)The Company is engaged in the manufacture of Active Pharmaceutical Ingredients and intermediates and the same constitutes a single reportable business segment as per Ind AS 108.(4)These financial results have been prepared in accordance with Indian Accounting Standards (�Ind AS�) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.(5)As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has opted to publish quarterly unaudited standalone results and to publish consolidated results at the year end.(6)The Ministry of Corporate Affairs (MCA) on 28th March 2018 notified Ind AS 115 �Revenue from contracts with customers� as part of the Companies (Indian Accounting Standards) Amendment Rules, 2018. The new Standard is effective for reporting periods beginning on or after 1st April 2018. The adoption of the standard did not have any material impact to the financial results of the company. 7. Post implementation of Goods and Service Tax (GST) effective from 1st July, 2017, revenue is reported net of GST as per Ind AS-18.� Revenue, however, is reported inclusive of excise duty for a part of the period ended 30th September, 2017.� Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:������������������������������������������������������������������������������������������������������������������������������������������������������������������� (Rs. in Lakhs)� Quarter ended Half Year ended Year ended� 30.09.2018 30.06.2018 30.09.2017 30.09.2018 30.09.2017 31.03.2018Revenue from operations (net of excise duty) �128500 �99531 �88752 �228031 �170015 �381735�8. Details of forex gain/(loss), grouped under Other Income, are given below:������������������������������������� �������������������������������������������������������������������������������������������������� (Rs. in Lakhs)� Quarter ended Half Year ended Year ended� 30.09.2018 30.06.2018 30.09.2017 30.09.2018 30.09.2017 31.03.2018Forex gain/(loss) 5278 2669 1059 7947 1760 24609. As approved by the Members of the company at the 28th Annual General Meeting held on 10th September, 2018, the company has disbursed on 19th September, 2018 a dividend of Rs. 10 per equity share of Rs. 2 each for the year ended 31st March, 2018, aggregating to Rs. 26547 lakhs.10. Figures for the previous periods/year have been regrouped/reclassified wherever necessary. 2018-04-01 2018-09-30 Unaudited Standalone 22803100000.00 1288400000.00 24091500000.00 9533000000.00 0.00 -986200000.00 2559900000.00 8800000.00 839900000.00 3036500000.00 14991900000.00 9099600000.00 0.00 9099600000.00 2332700000.00 128800000.00 2461500000.00 0.00 6638100000.00 0.00 0.00 0.00 6638100000.00 3400000.00 6641500000.00 0.00 0.00 0.00 0.00 530900000.00 2 25.01 25.01 0.00 0.00 25.01 25.01